

Troubled infant formula plant resumes production

July 11 2022



Credit: CC0 Public Domain

Abbott Inc. has announced that it has resumed production at its infant formula plant, following a February shutdown over contamination concerns that triggered a months-long shortage of infant formula.

The Sturgis, Mich., factory had restarted production earlier this summer, but had to [close](#) once again in mid-June because of damage from severe thunderstorms.

Production of Elecare, a specialty formula for infants with severe food allergies, began after a July 1 reboot, according to the company.

Additional formula will be produced soon, Abbott spokesman John Koval told the *Associated Press*.

"We are working to restart Similac production as soon as we can. We'll provide more information when we have it," Koval added.

Production first resumed in June with additional safety protocols after U.S. Food and Drug Administration inspectors [closed it](#) in February. The investigation had uncovered bacterial contamination, a leaky roof and lax safety.

The findings were discovered after the FDA began investigating bacterial infections among four infants who consumed baby formula. Two of the babies died, the *AP* reported.

Abbott has said its products have not been directly linked to the infections, which it noted involved different bacterial strains, according to the *AP*.

As parents and caregivers scoured shelves for formula amid short supplies, babies who had allergies, digestive problems and [metabolic disorders](#) were most significantly affected by the shortage. The shortage due to the plant shutdown was also compounded by supply chain disruptions and stockpiling during pandemic shutdowns.

Only four companies produce 90% of all formula sold in the United

States.

Abbott is among them, though Koval declined to say how much of Abbott's production happens at the Michigan plant, the *AP* reported.

Some of the shortage was alleviated when President Biden [relaxed rules](#) that restricted imports from foreign formula manufacturers. Millions of bottles of formula have been flown to the United States from Europe as a result.

The Biden administration also invoked federal [emergency rules](#) that prioritized formula production in the United States

The FDA now plans to work on long-term authorization for the European [formula](#) makers to market their products in the United States, to help keep supplies abundant in case of future shortages, the *AP* reported.

Closing the Sturgis plant "compounded by unforeseen natural weather events, has shown just how vulnerable the [supply chain](#) has become," said FDA Commissioner Dr. Robert Califf said in a recent [statement](#).

More information: The American Academy of Pediatrics has more on [feeding babies](#) during the formula shortage.

Copyright © 2022 [HealthDay](#). All rights reserved.

Citation: Troubled infant formula plant resumes production (2022, July 11) retrieved 27 April 2024 from <https://medicalxpress.com/news/2022-07-infant-formula-resumes-production.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is

provided for information purposes only.